We are developing oral antibody therapy solutions, with positive proof of concept results for C Difficile infection (now in phase 2 clinical trial), Traveler’s Diarrhea, Obesity, Acid Reflux, Arthritis, Asthma and IBS. Other potential targets include IBD, Covid-19, UTI, Stress, Anxiety, Depression, Heart Disease, Colorectal cancer, Alzheimer’s, Parkinson’s, Autism and many more. Not to mention Pet and Animal Health treatments as well as Environmental and Humanitarian opportunities.

Our Antibodies represent a very different Pharma medicine proposal. Like other Pharma’s we are developing Biologic treatments to various targeted diseases. Unlike other Pharma’s, we are doing this using a very safe and effective whole food substrate delivery system.

Our treatments can be targeted as per our C Difficile Antibodies (C DIFF FYX) to eliminate this bacterial infection, or be more general as per our ImmunAde Oral Antibodies taken daily to provide an extra serving of natural immunity, helping your Immune System keep Microbiome Dysbiosis in check and therefore maintain bacterial diversity, which correlates with good health.

As the World's first oral dosed Antibody Therapy (CFIA registered Hyper-Egg K88 to treat E Coli infection in food production animals, 2007), our Antibodies are a Safe, Effective and Affordable way of treating enteric infections and other health disorders.

J. H. Hare & Associates Ltd., was incorporated in Manitoba, Canada in 1970, by Dr. J. H. Hare. John S Hare acquired this company in 1987.

J. S. Hare & Associates Ltd., was incorporated in Delaware, USA in 1990.

Research started into "Hyper-Egg" Vaccine/Antibody therapy in 1997.

ImmuniMed Inc. was incorporated in 2012 to take our Clostridioides Difficile Antibody treatment through clinical trials and eventually to market.